60 results about "Active immunization" patented technology

The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.

The present invention relates to an amyloid β peptide analogues comprising an amino acid sequence or a peptidomimetic thereof, wherein the sequence (i) forms a loop, (ii) has at least 66% identity to the amino acid sequence of native Aβ peptide or a portion thereof, (iii) comprises at least 6 contiguous amino acid residues and (iv) has at least 2 non-contiguous amino acid residues which are covalently linked with each other, oligomers comprising a plurality of said amyloid β peptide analogues, processes for preparing the amyloid β peptide analogues or oligomers, compositions comprising the amyloid β peptide analogues or oligomers, and uses of the amyloid β peptide analogues or oligomers such as their use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the amyloid β peptide analogues or oligomers. The subject invention also describes agents that are capable of binding to the amyloid β peptide analogues or oligomers, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.

The present invention provides for methods for immunizing actively against autologous carcinoembryonic antigen (CEA). The method encompasses that the immune system is engaged with variant CEA which is either administered as a protein vaccine, or is effected expressed by nucleic acid vaccination or live-viral vaccination. Preferred embodiments include immunization with variants that include at least one foreign T-helper epitope introduced in the CEA sequence. Also disclosed is variant proteins, DNA, vectors, and host cells useful for practising the method of the invention.

The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.

The invention discloses a preparation method and application of Newcastle disease virus infected immune complex vaccines. The preparation method comprises the following steps of: (1) preparing antigens and inactivated vaccines by using Newcastle disease virus Shanghai strains as seed viruses; (2) transferring antibodies in chicken blood serum to yolk to form yolk antibodies IgY; and (3) mixing the prepared inactivated vaccines and the yolk antibodies IgY in equal volume, and hatching to obtain the immune complex vaccines. By combining passive immune (vaccine) and active immune (specific antibody) measures, animals are protected from the infection of pathogenic microbes in time for a long time.

Compositions and methods are provided which can be utilized in active immunization as a prophylactic treatment or a therapeutic treatment for tumors. The compositions are employed as injectable tumor vaccines or as preparations for intratumoral administration and are capable of stimulating immune responses to specific tumor antigens. The tumor vaccines are composed of an antigenic cellular material including a plurality of inactivated tumor cells or tumor cell portions, a depot material, and an immunostimulant adsorbed to the depot material. The depot material with absorbed immunostimulant is mixed with the tumor cells or tumor cell portions to form the vaccine compositions. The preparations for intratumoral administration include the depot material adsorbed immunostimulant without the antigenic cellular material. The immunostimulant adsorbed to the depot material permits release of biologically active quantities of the immunostimulant over a period of time rather than all at once.

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies. The invention provides means of blocking augmenting efficacy of immunotherapy, chemotherapy, and radiotherapy.

The invention discloses an interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals. The interleukin-4 therapeutic vaccine is a protein vaccine or coupling protein vaccine of any form prepared by taking the natural or artificially synthesized complete protein or protein fragment of interleukin-4 as an antigen; or the interleukin-4 therapeutic vaccine is a gene vaccine or fusion gene vaccine of any form prepared by taking the complete gene or gene fragment of interleukin-4 as the antigen gene or the major antigen gene. The IL (interleukin)-4 vaccine is used for performing active immunotherapy on a host, generally, the effective time lasts for about 2-3 months by immunization for the first time, the effective therapeutic time lasts for about half a year by secondary immunization, and recovery can be achieved by 1-3 times of immunotherapy. Compared with direct application of anti-IL-4 antibody for treatment, the invention has the characteristics of few times of application, low dose and the like, thereby greatly reducing the therapeutic cost, and also greatly reducing the possibility of generating allergic reaction.

The invention discloses two CD8+T cell dominant epitopes of VPNSSLVEN and SQFLSLSLL based on toxoplasmagondii bradyzoite specific surface antigens, wherein six CD8+T cell epitopes with H-2 restriction and high affinity are screened according to the protein sequences of the bradyzoite specific surface antigens of SAG2C, -2C and -2X; BALB/c mice are actively immunized by the screened epitope polypeptides; determinations for a lymphopoiesis level and a cell factor content, and an immune protection evaluation for epitope vaccines are performed after the immunization. The result indicates that powerful cell immunization can be generated by inducing the mice via the epitope vaccinesm, wherein the two antigen peptides of VPNSSLVEN and SQFLSLSLL are provided to be great in the capacity of stimulating T cell proliferation, as well as capable of inducing the mice to secrete protective cell factors and immune protection, being used as the epitope vaccines effectively resisting toxoplasmagondii infection, and reducing an encystations rate in the brain tissue of a host.

The invention discloses a DNA vaccine for preventing toxoplasmosis of humans or animals. An ROP19 gene is amplified through PCR, the amplified ROP19 gene is inserted into a eukaryotic expression vector pEGFP-C1 to build recombinant plasmid pEGFP-C1-ROP19 (pROP19), the recombinant plasmid containing a target gene is extracted, and the toxoplasma gondii ROP19DNA vaccine is obtained. According to the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, active immunization is conducted on BALB/c mice through the DNA vaccine, the immunogenicity of the vaccine is evaluated by determining cells and humoral immunity indexes of immunized mice, and the immunoprotectivity of the vaccine is estimated by counting the number of cysts in brains of the mice and the survival rate of the mice after attack experiments of toxoplasma gondii are conducted. By means of the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, humoral immunity and cellular immune responses can be effectively enhanced, the formation rate of the brain cysts of the immune mice attacked by a toxoplasma gondii PRU strain (II type) is effectively decreased, and the survival time of the mice attacked by a toxoplasma gondii RH stain (I type) is prolonged.

Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig⁺) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y¹⁰) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Y^hi) is predictive of a low anti tumor response.

Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.

The invention discloses a medicine for promoting growth and development of pigs as well as a preparation method and application of medicine and belongs to the technical field of livestock and poultrymedicines. The medicine disclosed by the invention is prepared from the following components in percentage by weight: 99 percent to 99.5 percent of a traditional Chinese medicine composition and 0.5 percent to 1 percent of bacillus subtilis, wherein the traditional Chinese medicine composition is prepared from radix astragali seu hedysari, folium eucommiae extract, radix codonopsis, bighead atractylodes rhizome, rhizoma dioscoreae, scorched fructus crataegi, scorched malt, scorched medicated leaven, orange peel and liquorice root according to the weight ratio of (4 to 15) to (2 to 5) to (4 to10) to (3 to 8) to (2 to 8) to (2 to 6) to (1 to 4) to (1 to 4) to (2 to 5) to (0.1 to 2). The medicine disclosed by the invention can be used for strengthening a gastrointestinal function and improving the feed conversion rate; less excrement is formed and the emission of waste gas is reduced. The medicine can be used for stimulating immune organ functions and improving the active immunization level. The medicine is used for promoting repairing and secondary development of internal organs, increasing the disease resistance and reducing the morbidity and the death.

The invention discloses a pure natural traditional Chinese medicine and marine organism active immunization bone. The active immunization bone provided by the invention is prepared from bone protein and a concentrated traditional Chinese medicinal solution. The pure natural traditional Chinese medicine and marine organism active immunization bone provided by the invention can rapidly stop bleeding in a part with fracture within a short time, prevent deformation, repair bone cells and promote rapid healing of a wound, enhance an antibacterial effect, nourish bones and muscles as well as tendons and periostea, and enhance a bone density. The pure natural traditional Chinese medicine and marine organism active immunization bone provided by the invention, when applied to osteosynthesis, can avoid pain in a patient who accepts a secondary operation to take out a steel body which is used for setting the fracture due to injury, atrophy and deformation on wound healing as well as complication infection, and can avoid the phenomenon that the patient becomes disabled due to a failed operation.

The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is a dengue antigen. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against dengue virus, preferably against dengue virus of any one of serotypes 1 to 4. Thus, the invention further provides methods of treating, ameliorating and/or preventing dengue virus infection by way of active immunization against domain III of the dengue virus envelope protein E, or against antigenic fragments thereof.

The invention relates to a reproducible RNA vaccine for control of toxoplasmosis. The method of the vaccine is as below: inserting a toxoplasmosis antigen gene NTPase-II into an alphavirus vector RREP to obtain a recombinant plasmid pRREP-NTPase-II; and before immunization, conducting in vitro transcription on the recombinant plasmid into RNA to obtain the reproducible RNA vaccine. The invention uses reproducible RNA vaccine for active immunization on BALB/c mice; cellular and humoral immune indexes of the immune mice are determined to evaluate the immunogenicity of the vaccine; through the observation of the survival time of acute Toxoplasma gondii infected mice and count of the number of cysts in brains of chronic Toxoplasma gondii infected mice, the immune protection of the vaccine can be evaluated. The vaccine can effectively enhance the humoral and cellular immune responses, effectively prolong the survival time of the mice after attack by Toxoplasma gondii RH strain (type I), and reduce the formation rate of brain cysts in the immune mice after attack by Toxoplasma gondii PRU strain (type II). The vaccine can be used as an effective candidate vaccine for control of acute and chronic Toxoplasma gondii infectio.